AI could help surgeons spot aggressive kidney tumors before operating

NCT ID NCT07166445

Recruiting now Diagnosis Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing whether a computer program (deep learning) can accurately tell the difference between early-stage (T1-T2) and more advanced (T3) kidney cancer on CT scans. Researchers will train the AI on 1,000 patients' scans and check its accuracy. If it works, the tool could be added to hospital systems to help surgeons plan the best treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this AI tool could help doctors more accurately stage kidney cancer before surgery, leading to better treatment decisions and fewer unnecessary operations.
What could go wrong: This is a retrospective study using existing images, not a real-world test. The AI may not perform as well in different hospitals or with different CT machines.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, RENAL CELL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

renal cell adenocarcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, RENAL CELL DEEP LEARNING DIAGNOSTIC IMAGING PATHOLOGY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Peking University First Hospital, Beijing,
RECRUITING

Beijing, China

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.